Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with known sarcoidosis 17~* Age 18 or greater~* Patients with documented pulmonary hypertension with a PA mean \> 25 mm as measured by cardiac catheterization within six months of entry into the study~* Patients with dyspnea~* Six minute walk distance of between 100 to 500 meters~* Patients on stable immunotherapy for their sarcoidosis, including prednisone, methotrexate, azathioprine, hydroxychloroquine, cyclophosphamide, thalidomide, and/or infliximab~* Patients able to provide written consent~Exclusion Criteria:~* Patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) in the prior 28 days (patients on stable dose of calcium channel blocker for more than 1 month prior to right heart catheterization can be continued on the calcium channel blocker)~* Patients with severe airway obstruction as defined by FEV1/FVC of less than 35%~* Patients with World Health Organization (WHO) class IV status~* Patients who are pregnant or breast feeding~* Patients with significant left ventricular dysfunction with a left ventricular ejection fraction of less than 35%~* Significant liver dysfunction not due to sarcoidosis~* Patients with severe other organ disease felt by investigators to impact survival during the course of the study~* Patients unable to perform the 6 inhalation treatments required for therapy~* Patients with \< 90 mm Hg Systolic systemic blood pressure will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).